Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 165
Filter
1.
Int. j. morphol ; 38(4): 940-946, Aug. 2020. tab, graf
Article in English | LILACS | ID: biblio-1124880

ABSTRACT

Solanum nigrum (SLN), commonly known as African nightshade, is used as a vegetable as well as in the management and treatment of various ailments including gastric ulcers. We analyzed, both grossly and microscopically using H&E, Masson's trichrome and PSA staining methods, the protective effects of aqueous leaf extracts of three Kenyan SLN genotypes namely S. scabrum (SSB), S. sarrachoides (SSR) and S. villosum (SVL) on ethanol-induced gastric lesions in rats. There was evidence of gastro-protection by all the three genotypes with the SSB showing the highest ulcer inhibition score (76.37 %) followed by SSR (72.51 %) and SVL (63.30 %). SLN-pretreated rats showed less areas of gastric mucosal surface erosion. Additionally in the pretreated animals, the depth of the ulcers were markedly reduced, reaching only the gastric pit region except in those treated with SVL where the ulcers penetrated slightly more deeply to affect the gastric glands. Compared with controls, the mean microscopic ulcer index decreased 5.07, 3.55 and 2.37-fold in rats pretreated with SSB, SSR and SVL extracts respectively. Results of this work show extracts of the three SLN genotypes to have antiulcerogenic potential but at varied strengths, thus confirming earlier reports that phytoconstituents and hence the efficacy of a medicinal plant may be influenced by genetic factors.


Solanum nigrum (SLN), comúnmente conocida como la solanácea africana, se usa como vegetal, para el tratamiento de diversas dolencias incluyendo las úlceras gástricas. Analizamos de forma macro y microscópica, de forma macroscópica y microscópica, utilizando para ello tinciones de H&E, tricrómico de Masson y PSA los efectos protectores de extractos acuosos de hojas de tres genotipos SLN de Kenia: S. scabrum (SSB), S. sarrachoides (SSR) and S. villosum (SVL) en lesiones gástricas inducidas por etanol en ratas. Hubo evidencia de gastroprotección por parte de los tres genotipos con el SSB mostrando el puntaje más alto de inhibición de la úlcera (76,37 %) seguido de SSR (72,51 %) y SVL (63,30 %). Las ratas tratadas previamente con SLN mostraron menos áreas de erosión de la superficie de la mucosa gástrica. Además, en los animales pretratados, la profundidad de las úlceras se redujo notablemente, llegando solo a la región del fondo gástrico, excepto en aquellos tratados con SVL donde las úlceras penetraron un poco más profundamente para afectar las glándulas gástricas. En comparación con los controles, el índice medio de úlcera microscópica disminuyó 5,07, 3,55 y 2,37 veces en ratas pretratadas con extractos de SSB, SSR y SVL, respectivamente. Los resultados de este trabajo muestran que los extractos de los tres genotipos de SLN tienen potencial antiulcerogénico en diferentes concentraciones, lo que confirma informes anteriores que los fitoconstituyentes y la eficacia de una planta medicinal pueden estar influenciados por factores genéticos.


Subject(s)
Animals , Rats , Stomach Ulcer/drug therapy , Plant Extracts/therapeutic use , Solanum nigrum/chemistry , Anti-Ulcer Agents/therapeutic use , Stomach/drug effects , Rats, Wistar , Protective Agents , Plant Preparations/pharmacology , Kenya , Anti-Ulcer Agents/pharmacology
2.
Braz. j. infect. dis ; 22(4): 311-316, July-Aug. 2018. tab, graf
Article in English | LILACS | ID: biblio-974231

ABSTRACT

ABSTRACT Aim To analyze the influence of the -31 C/T polymorphism of the interleukin-1β gene on Helicobacter pylori eradication therapy success in patients with functional dyspepsia. Methods Functional dyspepsia was diagnosed according to the Rome III criteria. All patients underwent upper gastrointestinal endoscopy, and gastric biopsies were obtained at screening and 12 months after randomization (last follow-up visit). Urease test and histological examination were performed to define the H. pylori status. Patients received twice-daily amoxicillin, clarithromycin and omeprazole for 10 days. Genotyping of the interleukin-1beta -31 C/T polymorphism (rs1143627) was performed using polymerase chain reaction-restriction fragment length polymorphism. Results One hundred forty-nine patients received treatment with triple therapy for H. pylori eradication. Only one patient was lost to follow-up, and adherence to study medication was 94.6%. A total of 148 patients (mean age 46.08 ± 12.24 years; 81.8% women) were evaluated for the influence of the interleukin-1beta -31 C/T polymorphism on the outcome of H. pylori eradication therapy. After treatment, bacteria were eradicated in 87% of patients (129/148). Genotype frequencies of the polymorphism were as follows: CC, 38/148 (25.7%); CT, 71/148 (47.9%); and TT, 39/148 (26.4%). Successful eradication rate was 78.9%, 94.4% and 82.1% for the CC, CT and TT genotypes, respectively. The CT genotype was significantly associated with successful H. pylori eradication (p= 0.039). Conclusion This study suggests that the CT genotype of the interleukin-1beta -31 C/T polymorphism plays a role in the successful eradication of H. pylori among patients with functional dyspepsia.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Polymorphism, Genetic , Helicobacter pylori/drug effects , Helicobacter Infections/drug therapy , Dyspepsia/drug therapy , Interleukin-1beta/genetics , Anti-Bacterial Agents/therapeutic use , Omeprazole/therapeutic use , Double-Blind Method , Follow-Up Studies , Helicobacter pylori/genetics , Treatment Outcome , Clarithromycin/therapeutic use , Dyspepsia/diagnosis , Genotype , Amoxicillin/therapeutic use , Anti-Ulcer Agents/therapeutic use
3.
Rev. gastroenterol. Perú ; 38(2): 128-130, abr.-jun. 2018. ilus
Article in English | LILACS | ID: biblio-1014070

ABSTRACT

Background: Helicobacter pylori infection which plays a major role in the etiology of chronic gastritis and duodenal ulcers in children and adults is one of the commonest chronic infection worldwide. Cure of the infection leads to healing of gastric inflammation and prevention of peptic ulcer. Objective: The aim of this study was to evaluate the efficacy of the sequential therapy for treatment of Helicobacter pylori infection. Materials and methods: In this study, 40 children with symptoms of H. Pylori that the infection was proved by endoscopy and biopsy and rapid urease test (UBT) were enrolled, and received sequential therapy (Lansoprazol, Amoxicillin) for 5 days and (Lansoprazol, Metronidazole and Clarithromycin) for next 5 days. The eradication rate of therapy was evaluated by stool antigen test 6 weeks after completion of therapy. This study was carried out in Pediatric Gastroenterology Clinic of Shiraz University of Medical Sciences, Shiraz, Iran. This study was approved by ethic committee of Shiraz University of Medical Sciences. Results: Forty children with mean age of (10.8±4 years) were evaluated. The most common symptom on first admission was epigastric pain (82.5%), with mean duration of symptoms (16±14.5 month). The most common endoscopic findings was redness and erosion of the antrum (55%) and the most pathologic findings was chronic gastritis (77.5%). The most drug adverse effect was nausea (22.5%). The eradication rate of sequential therapy was 82.5%. Conclusion: Eradication rate of sequential therapy was 82.5% among our cases.


Antecedentes: La infección por Helicobacter pylori, que juega un rol principal en la etiología de la gastritis crónica y las úlceras duodenales en niños y adultos, es una de las infecciones crónicas más comunes en el mundo. La cura de esta infección lleva a la cura de la inflamación gástrica y a la prevención de la úlcera péptica. Objetivo: Evaluar la eficacia de la terapia secuencial en el tratamiento de la infección por Helicobacter pylori. Material y métodos: En este estudio, se enrolaron 40 niños con síntomas en los que la infección por H. pylori se demostró por endocopía con biopsia y prueba rápida de ureasa (UBT) y recibieron terapia secuencial (Lansoprazol, Amoxicilina) por 5 días y (lansoprazol, metronidazol y clarotromicina) por otros 5 días. La tasa de erradicación de la terapia se evaluó por prueba de antígeno en heces 6 semanas después de terminar la terapia. Este estudio se llevó a cabo en la Clínica de Gastroenterología Pediátrica de la Universidad de Ciencias Médicas de Shiraz, Irán. El estudio fue aprobado por el comité de ética de la Universidad de Ciencias Médicas de Shiraz. Resultados: Se evaluaron cuarenta niños con una edad media de (10,8±4 años). El síntoma más común al ingreso fue dolor epigástrico (82,5%) con una duración media de síntomas de (16±14,5 meses). El hallazgo endoscópico más común fue enrojecimiento y erosión del antro (55%) y el hallazgo patológico más común fue gastritis crónica (77,5%). El evento adverso más común fue náusea (22,5%). La tasa de erradicación de la terapia secuencial fue 82,5%. Conclusión: La tasa de erradicación de la terapia secuencial fue de 82,5% en nuestros casos.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Helicobacter pylori , Helicobacter Infections/drug therapy , Anti-Ulcer Agents/therapeutic use , Anti-Bacterial Agents/therapeutic use , Drug Administration Schedule , Treatment Outcome , Clarithromycin/therapeutic use , Drug Therapy, Combination , Lansoprazole/therapeutic use , Amoxicillin/therapeutic use , Metronidazole/therapeutic use
5.
Acta cir. bras ; 31(12): 813-820, Dec. 2016. graf
Article in English | LILACS | ID: biblio-837660

ABSTRACT

ABSTRACT PURPOSE: To evaluate the role of low molecular chitosan containing sepia ink (LMCS) in ethanol-induced (5 ml/kg) gastric ulcer in rats. METHODS: Animals were divided into four groups (n = 12): normal group (Normal), negative control group (Con), experiment group (LMCS) and positive control Omeprazole group (OMZ). Gastric empty rate was detected in the first 7 days. Rats were sacrificed at 7, 14 and 21 day for histology and ELISA detections. RESULTS: Gastric empty was no significant differences among the groups (P > 0.05). Histological observation showed gastric mucosal LMCS treated had better healing effect. Hydroxyproline (Hyp) was significantly increased from 7 day (P < 0.05). LMCS significantly inhibited malondialdehyde (MDA) generation for lipid peroxidation from 7 day (P < 0.05). LMCS significantly promoted the activity of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) at the earlier stage (P < 0.05). OMZ had the similar effects above. As for myeloperoxidase (MPO), LMCS significantly decreased and restored it to normal levels from 7 day (P < 0.05), it is earlier than OMZ which is from 14 day. CONCLUSION: LMCS can improve gastric mucosa tissue repair, exert significant influences on oxidative and antioxidant enzyme activities and neutrophil infiltration.


Subject(s)
Animals , Rats , Stomach Ulcer/drug therapy , Chitosan/therapeutic use , Sepia/chemistry , Gastric Mucosa/drug effects , Anti-Ulcer Agents/therapeutic use , Antioxidants/pharmacology , Stomach Ulcer/chemically induced , Random Allocation , Chitosan/chemistry , Disease Models, Animal , Ethanol , Gastric Mucosa/pathology , Hydroxyproline/metabolism , Ink , Malondialdehyde/metabolism , Molecular Weight , Antioxidants/metabolism
6.
Arq. gastroenterol ; 53(3): 152-155, tab
Article in English | LILACS | ID: lil-787350

ABSTRACT

ABSTRACT Background Infection with Helicobacter pylori is highly prevalent worldwide, especially in developing countries. Its presence in the gastroduodenal mucosa is related with development of peptic ulcer and other illnesses. The eradication of H. pylori improves mucosal histology in patients with peptic ulcers. Objective This study was aimed to verify if H. pylori recurrence occurs five years or more after confirmed eradication in patients with peptic ulcer. Moreover, we sought to determine the recurrence rate. Methods Retrospective and longitudinal, this study was based on a sample of 201 patients from western Paraná, Brazil. The patients were diagnosed with peptic ulcer disease, in the period of 1990-2000, and followed for five years or more after successful H. pylori eradication. Patients with early recurrence - prior to five years after eradication - were excluded from the sample. Results During an average follow-up of 8 years, 180 patients (89.55%) remained negative, and 21 (10.45%) became positive for H. pylori infection. New ulcers appeared in two-thirds of the patients with H. pylori recurrence. Conclusion The recurrence of H. pylori in patients with peptic ulcer can occur in the long-term - even if the infection had been successfully eradicated and the patients had remained free of recurrence in the first years of follow-up.


RESUMO Contexto A infecção por Helicobacter pylori é altamente prevalente no mundo, especialmente nos países em desenvolvimento, e sua presença na mucosa gastroduodenal está associada com o desenvolvimento de úlcera péptica e outras patologias. A erradicação do H. pylori melhora a histologia da mucosa em pacientes com úlcera péptica. Objetivo Determinar se a recorrência da infecção por H. pylori ocorre cinco anos ou mais após a erradicação confirmada em pacientes com úlcera péptica. Além disso, buscou-se determinar a taxa de recorrência. Método Retrospectivo e longitudinal, o estudo foi baseado em uma amostra de 201 pacientes oriundos da região Oeste do Paraná, Brasil. Os pacientes foram diagnosticados com úlcera gástrica e/ou duodenal, no período de 1990-2000, e foram seguidos por pelo menos cinco anos após a erradicação com sucesso do H. pylori. Pacientes com recorrência precoce - nos primeiros cinco anos após a erradicação - foram excluídos da amostra. Resultados - Após um tempo médio de seguimento de oito anos, 180 pacientes (89,55%) permaneceram negativos e 21 (10,45%) tornaram-se positivos para a presença de H. pylori. Novas úlceras apareceram em dois terços dos pacientes com recorrência da bactéria. Conclusão A recorrência da infecção por H. pylori ocorre em longo prazo - mesmo se a infecção tiver sido erradicada com sucesso e os pacientes permanecido livres de recorrência nos primeiros cinco anos de seguimento.


Subject(s)
Humans , Male , Female , Adult , Peptic Ulcer/epidemiology , Helicobacter pylori , Helicobacter Infections/epidemiology , Peptic Ulcer/drug therapy , Recurrence , Time Factors , Brazil/epidemiology , Retrospective Studies , Follow-Up Studies , Longitudinal Studies , Helicobacter Infections/prevention & control , Helicobacter Infections/drug therapy , Drug Therapy, Combination , Middle Aged , Anti-Ulcer Agents/therapeutic use , Anti-Bacterial Agents/therapeutic use
7.
Braz. j. med. biol. res ; 49(2): e5080, 2016. tab, graf
Article in English | LILACS | ID: biblio-951656

ABSTRACT

We aimed to evaluate the effectiveness and safety of bismuth-containing quadruple therapy plus postural change after dosing for Helicobacter pylori eradication in gastrectomized patients. We compared 76 gastric stump patients with H. pylori infection (GS group) with 50 non-gastrectomized H. pylori-positive patients who met the treatment indication (controls). The GS group was divided into GS group 1 and GS group 2. All groups were administered bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days. GS group 1 maintained a left lateral horizontal position for 30 min after dosing. H. pylori was detected using rapid urease testing and histologic examination of gastric mucosa before and 3 months after therapy. Mucosal histologic manifestations were evaluated using visual analog scales of the updated Sydney System. GS group 1 had a higher prevalence of eradication than the GS group 2 (intention-to-treat [ITT]: P=0.025; per-protocol [PP]: P=0.030), and the control group had a similar prevalence. GS group 2 had a lower prevalence of eradication than controls (ITT: P=0.006; PP: P=0.626). Scores for chronic inflammation and activity declined significantly (P<0.001) 3 months after treatment, whereas those for atrophy and intestinal metaplasia showed no significant change. Prevalence of adverse reactions was similar among groups during therapy (P=0.939). A bismuth-containing quadruple therapy regimen plus postural change after dosing appears to be a relatively safe, effective, economical, and practical method for H. pylori eradication in gastrectomized patients.


Subject(s)
Humans , Male , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Helicobacter pylori/drug effects , Helicobacter Infections/therapy , Gastric Stump , Gastrectomy , Anti-Bacterial Agents/therapeutic use , Organometallic Compounds/therapeutic use , Treatment Outcome , Potassium Citrate/therapeutic use , Drug Therapy, Combination/methods , Patient Positioning/statistics & numerical data , Esomeprazole/therapeutic use , Furazolidone/therapeutic use , Amoxicillin/therapeutic use , Metaplasia , Anti-Ulcer Agents/therapeutic use
11.
The Korean Journal of Gastroenterology ; : 70-74, 2015.
Article in Korean | WPRIM | ID: wpr-118741

ABSTRACT

The prevalence of gastroesophageal reflux disease (GERD) in South Korea has increased over the past 10 years. Patients with erosive reflux disease (ERD) shows better response to proton pump inhibitors (PPIs) than those with non-erosive reflux disease (NERD). NERD is a heterogeneous condition, showing pathological gastroesophageal reflux or esophageal hypersensitivity to reflux contents. NERD patients with pathological gastroesophageal reflux or hypersensitivity to acid may respond to PPIs. However, many patients with esophageal hypersensitivity to nonacid or functional heartburn do not respond to PPIs. Therefore, careful history and investigations are required when managing patients with refractory GERD who show poor response to conventional dose PPIs. Combined pH-impedance studies and a PPI diagnostic trial are recommended to reveal underlying mechanisms of refractory symptoms. For those with ongoing reflux-related symptoms, split dose administration, change to long-acting PPIs or PPIs less influenced by CYP2C19 genotypes, increasing dose of PPIs, and the addition of alginate preparations, prokinetics, selective serotonin reuptake inhibitors, or tricyclic antidepressants can be considered. Pain modulators, selective serotonin reuptake inhibitors, or tricyclic antidepressants are more likely to be effective for those with reflux-unrelated symptoms. Surgery or endoscopic per oral fundoplication may be effective in selected patients.


Subject(s)
Humans , Anti-Ulcer Agents/therapeutic use , Cytochrome P-450 CYP2C19/genetics , Esophageal pH Monitoring , Gastroesophageal Reflux/drug therapy , Genotype , Heartburn , Proton Pump Inhibitors/therapeutic use
12.
Acta cir. bras ; 29(9): 544-552, 09/2014. graf
Article in English | LILACS | ID: lil-722131

ABSTRACT

PURPOSE: To evaluate the effects of sucralfate on tissue content of neutral and acids mucins in rats with diversion colitis. METHODS: Thirty-six rats were submitted to a proximal right colostomy and a distal mucous fistula. They were divided into two groups according to sacrifice to be performed two or four weeks after intervention. Each group was divided into three subgroups according daily application of enemas containing saline, sucralfate at 1.0 g/kg/day or 2.0 g/kg/day. Colitis was diagnosed by histological analysis and neutral and acid mucins by Periodic Acid Schiff and Alcian Blue techniques, respectively. The contents of mucins were quantified by computer-assisted image analysis. Student's t paired and ANOVA test were used to compare the contents of both types of mucins among groups, and to verify the variance with time, establishing level of signification of 5% for both (p<0.05). RESULTS: Enemas containing sucralfate improves the inflammation and increases the tissue contents of neutral and acid mucins. The content of neutral mucins does not change with the time or concentration of sucralfate used, while acid mucins increases with concentration and time of intervention. CONCLUSIONS: Sucralfate enemas improve the inflammatory process and increase the tissue content of neutral and acid mucins in colon without fecal stream. .


Subject(s)
Animals , Male , Anti-Ulcer Agents/therapeutic use , Colitis/drug therapy , Enema/methods , Membrane Glycoproteins/analysis , Mucins/analysis , Sucralfate/therapeutic use , Anti-Ulcer Agents/pharmacology , Colitis/pathology , Colon/drug effects , Colon/pathology , Disease Models, Animal , Image Processing, Computer-Assisted , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Mucins/drug effects , Rats, Wistar , Reproducibility of Results , Sucralfate/pharmacology , Time Factors , Treatment Outcome
13.
Arq. gastroenterol ; 51(1): 64-67, Jan-Mar/2014. tab, graf
Article in English | LILACS | ID: lil-707004

ABSTRACT

Context Ulcer is the most common gastrointestinal disturbance resulting from an inadequate gastric mucosal defense. Several drugs are available in the market to address the disease; however, these drugs are associated with unnecessary side effects. Objectives Previous research have confirmed the efficacy of plant extracts for possible treatment of the disease. This research aims to evaluate the anti-ulcer properties of medicinal plants. Methods Methanol extracts from the leaves of Intsia bijuga, Cynometra ramiflora, Tamarindus indica, Cassia javanica, Cassia fistula, Bauhini purpurea, Senna spectabilis, Senna siamea and Saraca thaipingensis were evaluated for their anti-ulcer activity using HCl-ethanol as ulcerogen. Results All extracts showed inhibitory activity with I. bijuga, T. indica, S. spectabilis and S. thaipingensis exhibiting more than 50% inhibition. S. thaipingensis showed the highest activity at 80%. S. spectabilis and S. thaipingensis were partitioned further into hexane, ethyl acetate and aqueous fractions. The aqueous and ethyl acetate fractions of S. spectabilis showed significant increased in its activity while the hexane and ethyl acetate fractions of S. thaipingensis gave higher activity than its aqueous portions. Conclusions We conclude that plant extracts are potential sources of new anti-ulcer agents. .


Contexto A úlcera é o distúrbio gastrointestinal mais comum que resulta de uma inadequada defesa da mucosa gástrica. Vários medicamentos estão disponíveis no mercado para tratar a doença, no entanto, estas drogas podem se associar a efeitos colaterais desnecessários. Objetivos Pesquisas anteriores confirmaram a eficácia de extratos de plantas como possível tratamento da doença. Esta pesquisa teve como objetivo avaliar as propriedades anti-úlcera de plantas medicinais. Métodos Extratos alcoólicos das folhas da Intsia bijuga, Cynometra ramiflora, Tamarindus indica, Cassia javanica, Cassia fistula, Bauhini purpurea, Senna spectabilis, Senna siamea e Saraca thaipingensis foram avaliados pela sua atividade anti-úlcera usando o HCl-etanol como ulcerogênico. Resultados Todos os extratos apresentaram atividade inibitória; I.bijuga, T. Índica, S. spectabilis e S. thaipingensis mostraram mais de 50% de inibição. A S. thaipingensis mostrou a maior atividade, atingindo 80%. S. spectabilis e S. thaipingensis foram divididos mais em hexano, acetato de etila e frações aquosas. As frações aquosas e acetato de etila de S. spectabilis mostraram aumento significativo em sua atividade, enquanto que as frações hexano e acetato de etila de S. thaipingensis resultaram em maior atividade do que em partes aquosas. Conclusões Pode-se concluir que os extratos vegetais são fontes potenciais de novos agentes anti-úlcera. .


Subject(s)
Animals , Mice , Anti-Ulcer Agents/therapeutic use , Fabaceae/chemistry , Plant Extracts/therapeutic use , Stomach Ulcer/drug therapy , Disease Models, Animal , Fabaceae/classification
14.
Gut and Liver ; : 605-611, 2014.
Article in English | WPRIM | ID: wpr-55224

ABSTRACT

BACKGROUND/AIMS: Retreatment after initial treatment failure for Helicobacter pylori is very challenging. The purpose of this study was to evaluate the efficacies of moxifloxacin-containing triple and bismuth-containing quadruple therapy. METHODS: A total of 151 patients, who failed initial H. pylori treatment, were included in this retrospective cohort study. The initial regimens were standard triple, sequential, or concomitant therapy, and the efficacies of the two following second-line treatments were evaluated: 7-day moxifloxacin-containing triple therapy (rabeprazole 20 mg twice a day, amoxicillin 1,000 mg twice a day, and moxifloxacin 400 mg once daily) and 7-day bismuth-containing quadruple therapy (rabeprazole 20 mg twice a day, tetracycline 500 mg 4 times a day, metronidazole 500 mg 3 times a day, and tripotassium dicitrate bismuthate 300 mg 4 times a day). RESULTS: The overall eradication rates after moxifloxacin-containing triple therapy and bismuth-containing quadruple therapy were 69/110 (62.7%) and 32/41 (78%), respectively. Comparison of the two regimens was performed in the patients who failed standard triple therapy, and the results revealed eradication rates of 14/28 (50%) and 32/41 (78%), respectively (p=0.015). The frequency of noncompliance was not different between the two groups, and there were fewer adverse effects in the moxifloxacin-containing triple therapy group (2.8% vs 7.3%, p=0.204 and 25.7% vs 43.9%, p=0.031, respectively). CONCLUSIONS: Moxifloxacin-containing triple therapy, a recommended second-line treatment for initial concomitant or sequential therapy failure, had insufficient efficacy.


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Breath Tests , Cohort Studies , Drug Therapy, Combination , Fluoroquinolones/therapeutic use , Gastroesophageal Reflux/complications , Helicobacter Infections/complications , Helicobacter pylori , Metronidazole/therapeutic use , Organometallic Compounds/therapeutic use , Peptic Ulcer/complications , Rabeprazole/therapeutic use , Republic of Korea , Retrospective Studies , Salvage Therapy , Stomach/pathology , Tetracycline/therapeutic use , Treatment Failure , Treatment Outcome , Urea/analysis
15.
Journal of Korean Medical Science ; : 704-713, 2014.
Article in English | WPRIM | ID: wpr-60728

ABSTRACT

Proton pump inhibitor (PPI)-based triple therapy consisting of PPI, amoxicillin, and clarithromycin, is the recommended first-line treatment for Helicobacter pylori infection. However, the eradication rate of triple therapy has declined over the past few decades. We analyzed the eradication rate and adverse events of triple therapy to evaluate current practices in Korea. A comprehensive literature search was performed up to August 2013 of 104 relevant studies comprising 42,124 patients. The overall eradication rate was 74.6% (95% confidence interval [CI], 72.1%-77.2%) by intention-to-treat analysis and 82.0% (95% CI, 80.8%-83.2%) by per-protocol analysis. The eradication rate decreased significantly from 1998 to 2013 (P < 0.001 for both intention-to-treat and per-protocol analyses). Adverse events were reported in 41 studies with 8,018 subjects with an overall incidence rate of 20.4% (95% CI, 19.6%-21.3%). The available data suggest that the effectiveness of standard triple therapy for H. pylori eradication has decreased to an unacceptable level. A novel therapeutic strategy is warranted to improve the effectiveness of first-line treatment for H. pylori infection in Korea.


Subject(s)
Humans , Alkylating Agents/therapeutic use , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Clarithromycin/therapeutic use , Communicable Disease Control , Cytochrome P-450 CYP3A Inhibitors/therapeutic use , Disease Eradication , Drug Resistance, Bacterial , Drug Therapy, Combination , Gastritis/microbiology , Helicobacter Infections/drug therapy , Helicobacter pylori , Metronidazole/therapeutic use , Proton Pump Inhibitors/therapeutic use , Republic of Korea , Tinidazole/therapeutic use
16.
Gut and Liver ; : 752-755, 2013.
Article in English | WPRIM | ID: wpr-209548

ABSTRACT

Solitary rectal ulcer syndrome (SRUS) is a rare, benign disorder in children that usually presents with rectal bleeding, constipation, mucous discharge, prolonged straining, tenesmus, lower abdominal pain, and localized pain in the perineal area. The underlying etiology is not well understood, but it is secondary to ischemic changes and trauma in the rectum associated with paradoxical contraction of the pelvic floor and the external anal sphincter muscles; rectal prolapse has also been implicated in the pathogenesis. This syndrome is diagnosed based on clinical symptoms and endoscopic and histological findings, but SRUS often goes unrecognized or is easily confused with other diseases such as inflammatory bowel disease, amoebiasis, malignancy, and other causes of rectal bleeding such as a juvenile polyps. SRUS should be suspected in patients experiencing rectal discharge of blood and mucus in addition to previous disorders of evacuation. We herein report six pediatric cases with SRUS.


Subject(s)
Adolescent , Child , Female , Humans , Male , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anti-Ulcer Agents/therapeutic use , Colonoscopy , Gastrointestinal Hemorrhage/diagnosis , Mesalamine/therapeutic use , Rectal Diseases/diagnosis , Steroids/therapeutic use , Sucralfate/therapeutic use , Syndrome , Ulcer/diagnosis
18.
Article in English | IMSEAR | ID: sea-157373

ABSTRACT

The present study was carried out to see the effect of two zinc salts i.e zinc sulphate and zinc chloride on gastric ulcers induced by stress, pylorus ligation and aspirin in albino rats. The rats were divided into two main groups (zinc sulphate 30, 60, 90 mg/kg i.p and zinc chloride 10 and 20mg/kg i.p). They were further sub-divided into three sub-groups dependant on ulcer model i.e stress, pylorus ligation and aspirin induced ulcers. It was found that zinc sulphate and zinc chloride had a dose dependant reduction in ulcer index in all three models of gastric ulceration. Also, both the salts had anti acid secretory effect, raised pH of gastric secretion and reduced total acidity significantly. Thus zinc salts prevent gastric ulceration. Probably this effect is mediated by anti acid secretory action.


Subject(s)
Animals , Anti-Ulcer Agents/pharmacology , Anti-Ulcer Agents/therapeutic use , Aspirin/adverse effects , Gastric Acid/drug effects , Gastric Acid/metabolism , Peptic Ulcer/chemically induced , Peptic Ulcer/drug therapy , Peptic Ulcer/etiology , Peptic Ulcer/prevention & control , Pylorus/physiology , Rats , Secretory Rate , Zinc Sulfate/therapeutic use
19.
The Korean Journal of Gastroenterology ; : 195-218, 2012.
Article in Korean | WPRIM | ID: wpr-12468

ABSTRACT

In 2010, a Korean guideline for the management of gastroesophageal reflux disease (GERD) was made by the Korean Society of Neurogastroenterology and Motility, in which the definition and diagnosis of GERD were not included. The aim of this guideline was to update the clinical approach to the diagnosis and management of GERD in adult patients. This guideline was developed by the adaptation process of the ADAPTE framework. Twelve guidelines were retrieved from initial queries through the Appraisal of Guidelines for Research & Evaluation II process. Twenty-seven statements were made as a draft and revised by modified Delphi method. Finally, 24 consensus statements for the definition (n=4), diagnosis (n=7) and management (n=13) of GERD were developed. Multidisciplinary experts participated in the development of the guideline, and the external review of the guideline was conducted at the finalization phase.


Subject(s)
Humans , Antacids/therapeutic use , Anti-Ulcer Agents/therapeutic use , Antidepressive Agents/therapeutic use , Barrett Esophagus/complications , Databases, Factual , Diet , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Endoscopy, Digestive System , Esophageal pH Monitoring , Gastroesophageal Reflux/complications , Histamine Antagonists/therapeutic use , Peptic Ulcer/complications , Proton Pump Inhibitors/therapeutic use , Stomach Neoplasms/complications
20.
Arq. gastroenterol ; 48(4): 276-282, Oct.-Dec. 2011. ilus, tab
Article in English | LILACS | ID: lil-607509

ABSTRACT

CONTEXT: The cabbage (Brassica oleraceae var. capitata) is an herbaceous and leafy plant which belongs to the Brassicaceae family, native to coastal southern and Western Europe. Used in cooking for its nutritional value also has known anti-inflammatory activity. OBJECTIVE We studied the antiulcerogenic activity of aqueous extract of Brassica oleracea var. capitata (AEB) in order to validate ethnobotanical claims regarding the plant use in the gastric disorders. METHOD: Acute gastric ulcers were induced in rats by the oral administration of acetylsalicylic acid. The gastroprotective potential of the AEB (0.250, 0.500 and 1.000 mg.kg-1/body weight) was compared with omeprazole (20 mg.kg-1/body weight). RESULTS: The stomach analysis indicated that treatment with AEB inhibited the gastric damage. The gastroprotective activity as evidenced by its significant inhibition in the formation of ulcers induced by chemical agent with a maximum of 99.44 percent curation (250 mg.kg-1 body weight) in acetylsalicylic acid-induced ulcers. CONCLUSIONS: The AEB demonstrated good antiulcerogenic activities which justify the inclusion of this plant in the management of gastric disorders. Further experiments are underway to determine which antiulcer mechanisms involved in gastroprotection.


CONTEXTO: O repolho (Brassica oleracea var. capitata) é uma planta de folhas herbáceas pertencente à família Brassicaceae, nativa na costa sul e oeste da Europa. Usado na culinária por seu valor nutritivo, possui conhecida atividade anti-inflamatória. OBJETIVO: Avaliar a atividade antiulcerogênica do extrato aquoso de Brassica oleracea var. capitata (AEB), a fim de validar os conhecimentos etnobotânico do uso da espécie em distúrbios gástricos. MÉTODO: Úlceras gástricas foram induzidas em ratos pela administração oral de ácido acetilsalicílico. O potencial gastroprotetor de AEB (0,250, 0,500 e 1,000 mg.kg-1/peso) foram comparados com omeprazol (20 mg.kg-1/peso). RESULTADOS: As análises dos estômagos indicaram que o tratamento com AEB inibiu a progressão da lesão gástrica. A atividade gastroprotetora foi evidenciada por sua significativa inibição da progressão da úlcera induzida por agentes químicos, com o máximo de 99,44 por cento eficácia (250 mg.kg-1/peso) frente a úlceras gástricas induzidas por ácido acetilsalicílico. CONCLUSÕES: O AEB demonstrou atividade cicatrizante de úlceras gástricas, o que justifica a inclusão da espécie em tratamentos de distúrbios gástricos. Estudos futuros estão em andamento para determinar quais os mecanismos antiulcerogêncios estão envolvidos com a gastroproteção.


Subject(s)
Animals , Male , Rats , Anti-Ulcer Agents/therapeutic use , Brassica/chemistry , Omeprazole/therapeutic use , Plant Extracts/therapeutic use , Stomach Ulcer/drug therapy , Aspirin , Gastric Mucosa/pathology , Rats, Wistar , Stomach Ulcer/chemically induced , Stomach Ulcer/pathology
SELECTION OF CITATIONS
SEARCH DETAIL